JP2009512719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512719A5 JP2009512719A5 JP2008536890A JP2008536890A JP2009512719A5 JP 2009512719 A5 JP2009512719 A5 JP 2009512719A5 JP 2008536890 A JP2008536890 A JP 2008536890A JP 2008536890 A JP2008536890 A JP 2008536890A JP 2009512719 A5 JP2009512719 A5 JP 2009512719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkynyl
- cycloalkyl
- alkenyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 17
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 102000009058 Death Domain Receptors Human genes 0.000 claims 7
- 108010049207 Death Domain Receptors Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 5
- 108700012411 TNFSF10 Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003607 modifier Substances 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 229940044601 receptor agonist Drugs 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000007801 affinity label Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 229940113306 Ligase inhibitor Drugs 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037012 chymotrypsin-like activity Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 108010093036 interleukin receptors Proteins 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000436 ligase inhibitor Substances 0.000 claims 1
- 229950001869 mapatumumab Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 1
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 0 C*(C)NC(N*C1CC1)=O Chemical compound C*(C)NC(N*C1CC1)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72972705P | 2005-10-25 | 2005-10-25 | |
| US83066206P | 2006-07-14 | 2006-07-14 | |
| PCT/CA2006/001721 WO2007048224A1 (en) | 2005-10-25 | 2006-10-20 | Iap bir domain binding compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009512719A JP2009512719A (ja) | 2009-03-26 |
| JP2009512719A5 true JP2009512719A5 (https=) | 2009-12-03 |
Family
ID=37965208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536890A Pending JP2009512719A (ja) | 2005-10-25 | 2006-10-20 | Ｉａｐｂｉｒドメイン結合化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7589118B2 (https=) |
| EP (1) | EP1951698A4 (https=) |
| JP (1) | JP2009512719A (https=) |
| KR (1) | KR20080067357A (https=) |
| AU (1) | AU2006308453B9 (https=) |
| BR (1) | BRPI0617751A2 (https=) |
| CA (1) | CA2564872C (https=) |
| IL (1) | IL190936A0 (https=) |
| RU (1) | RU2418807C2 (https=) |
| WO (1) | WO2007048224A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005274937B2 (en) * | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| WO2007106192A2 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| BRPI0708942A2 (pt) * | 2006-03-21 | 2011-06-14 | Joyant Pharmaceuticals Inc | composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica |
| AU2007250443B2 (en) | 2006-05-16 | 2013-06-13 | Pharmascience Inc. | IAP BIR domain binding compounds |
| WO2008014229A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| KR20090041391A (ko) * | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 ｉａｐ 길항제 |
| CL2007002166A1 (es) * | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20130150A1 (es) * | 2007-04-30 | 2013-02-27 | Genentech Inc | Inhibidores de las iap |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| WO2008144925A1 (en) * | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| US20120141496A1 (en) * | 2007-12-17 | 2012-06-07 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| ES2398791T3 (es) * | 2008-01-11 | 2013-03-21 | Genentech, Inc. | Inhibidores de IAP |
| WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| WO2009155709A1 (en) * | 2008-06-27 | 2009-12-30 | Aegera Therapeutics Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
| CN102171209A (zh) * | 2008-08-02 | 2011-08-31 | 健泰科生物技术公司 | Iap抑制剂 |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US8779280B2 (en) * | 2009-08-18 | 2014-07-15 | Lg Electronics Inc. | Solar cell and method of manufacturing the same |
| EP2784076A1 (en) | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
| WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| NZ602392A (en) * | 2010-03-18 | 2014-03-28 | Innopharma Inc | Stable bortezomib formulations |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| CA2850330A1 (en) | 2011-09-30 | 2013-04-04 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| CN105451726B (zh) | 2013-06-25 | 2021-03-16 | 沃尔特和伊利莎豪医学研究所 | 治疗细胞内感染的方法 |
| WO2015187998A2 (en) | 2014-06-04 | 2015-12-10 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| CN113677399B (zh) * | 2019-04-05 | 2024-10-11 | 和博医药有限公司 | 凋亡蛋白抑制剂的二价拮抗剂 |
| WO2021020585A1 (ja) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | 複素環化合物 |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| WO2024165017A1 (zh) * | 2023-02-08 | 2024-08-15 | 成都先导药物开发股份有限公司 | 杂环化合物及其用途 |
| KR102848239B1 (ko) * | 2023-04-13 | 2025-08-19 | 성신여자대학교 연구 산학협력단 | 비천연 아미노산을 포함하는 htra 표적 테트라펩타이드 프로브 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0680077B2 (ja) | 1985-02-08 | 1994-10-12 | サントリー株式会社 | プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物 |
| US5750646A (en) * | 1987-09-24 | 1998-05-12 | The Administrators Of The Tulane Educational Fund | Bradykinin analogs with non-peptide bond |
| GB9016810D0 (en) | 1990-07-31 | 1990-09-12 | Wellcome Found | Peptides |
| JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
| US5387671A (en) | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| KR100213201B1 (ko) * | 1996-05-15 | 1999-08-02 | 윤종용 | 씨모스 트랜지스터 및 그 제조방법 |
| US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| BRPI9911756B1 (pt) | 1998-06-30 | 2016-06-14 | Helsinn Healthcare Sa | composto, uso do mesmo, e composição farmaceutica |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| CA2449168A1 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| US20060258581A1 (en) | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2004005248A1 (en) * | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| ATE415413T1 (de) | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
| US7229617B2 (en) | 2002-11-27 | 2007-06-12 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
| WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
| CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| KR20060126548A (ko) | 2004-02-05 | 2006-12-07 | 노파르티스 아게 | (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물 |
| CN1926118A (zh) | 2004-03-01 | 2007-03-07 | 德克萨斯大学董事会 | 二聚的小分子细胞凋亡增强剂 |
| WO2005094818A1 (en) | 2004-03-23 | 2005-10-13 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| BRPI0511350A (pt) | 2004-07-02 | 2007-12-04 | Genentech Inc | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
| US20070003535A1 (en) | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
| DE102005017116A1 (de) | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
| US7772177B2 (en) * | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| EP1888619B1 (en) | 2005-05-25 | 2013-04-17 | 2cureX ApS | Compounds modifying apoptosis |
| JP2008545780A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| WO2007021825A2 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| WO2007106192A2 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| WO2007075525A2 (en) | 2005-12-20 | 2007-07-05 | Novartis Ag | Combination of an iap-inhibitor and a taxane7 |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| BRPI0708942A2 (pt) | 2006-03-21 | 2011-06-14 | Joyant Pharmaceuticals Inc | composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica |
| JP5230610B2 (ja) | 2006-05-05 | 2013-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 二価ｓｍａｃ模倣物およびその使用 |
| AU2007250443B2 (en) | 2006-05-16 | 2013-06-13 | Pharmascience Inc. | IAP BIR domain binding compounds |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| KR20090041391A (ko) | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 ｉａｐ 길항제 |
| CL2007002166A1 (es) | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| WO2008014229A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| US8044209B2 (en) | 2006-10-12 | 2011-10-25 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| KR20090082221A (ko) | 2006-10-19 | 2009-07-29 | 노파르티스 아게 | 유기 화합물 |
| CN101541325A (zh) | 2006-11-28 | 2009-09-23 | 诺瓦提斯公司 | Iap抑制剂用于治疗急性髓性白血病的用途 |
| KR20090087094A (ko) | 2006-11-28 | 2009-08-14 | 노파르티스 아게 | Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물 |
| ATE542798T1 (de) | 2006-12-07 | 2012-02-15 | Novartis Ag | Organische verbindungen |
| US8063218B2 (en) | 2006-12-19 | 2011-11-22 | Genentech, Inc. | Imidazopyridine inhibitors of IAP |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| PE20130150A1 (es) | 2007-04-30 | 2013-02-27 | Genentech Inc | Inhibidores de las iap |
| WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| WO2009136290A1 (en) | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US9750729B2 (en) | 2008-05-16 | 2017-09-05 | Dana-Farber Cancer Institute, Inc. | Immunomodulation by IAP inhibitors |
| TW201011006A (en) | 2008-06-16 | 2010-03-16 | Nuevolution As | IAP binding compounds |
| WO2009155709A1 (en) | 2008-06-27 | 2009-12-30 | Aegera Therapeutics Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
| CN102171209A (zh) | 2008-08-02 | 2011-08-31 | 健泰科生物技术公司 | Iap抑制剂 |
| WO2010015090A1 (en) | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| AU2009293403A1 (en) | 2008-09-17 | 2010-03-25 | Tetralogic Pharmaceuticals Corp. | IAP inhibitors |
| US20110177060A1 (en) | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
-
2006
- 2006-10-20 WO PCT/CA2006/001721 patent/WO2007048224A1/en not_active Ceased
- 2006-10-20 EP EP06790872A patent/EP1951698A4/en not_active Withdrawn
- 2006-10-20 US US11/583,816 patent/US7589118B2/en not_active Expired - Fee Related
- 2006-10-20 JP JP2008536890A patent/JP2009512719A/ja active Pending
- 2006-10-20 CA CA2564872A patent/CA2564872C/en not_active Expired - Fee Related
- 2006-10-20 AU AU2006308453A patent/AU2006308453B9/en not_active Ceased
- 2006-10-20 BR BRPI0617751-4A patent/BRPI0617751A2/pt not_active IP Right Cessation
- 2006-10-20 RU RU2008120408/04A patent/RU2418807C2/ru not_active IP Right Cessation
- 2006-10-20 KR KR1020087012374A patent/KR20080067357A/ko not_active Withdrawn
- 2006-12-01 US US11/606,883 patent/US7547724B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/607,998 patent/US7795298B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/607,964 patent/US8063095B2/en not_active Expired - Fee Related
-
2008
- 2008-04-17 IL IL190936A patent/IL190936A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512719A5 (https=) | ||
| JP2009529544A5 (https=) | ||
| NZ582089A (en) | Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir | |
| JP2011511840A5 (https=) | ||
| JP2019537570A5 (https=) | ||
| RU2008120408A (ru) | Соединения, связывающие bir домены iap | |
| JP2017528488A5 (https=) | ||
| JP2020516621A5 (https=) | ||
| JP2017528524A5 (https=) | ||
| US20090054415A1 (en) | Combinations, methods and compositions for treating cancer | |
| JP2009537461A5 (https=) | ||
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| JP2010515709A5 (https=) | ||
| JP2017504611A (ja) | 組合せ医薬 | |
| RU2017109912A (ru) | Лечение антителами против vegf | |
| Winer et al. | A review of omacetaxine: a chronic myeloid leukemia treatment resurrected | |
| JP2017528487A5 (https=) | ||
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| KR20210002015A (ko) | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
| RU2018128796A (ru) | Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта | |
| CN103327977A (zh) | 恶液质的治疗或预防剂 | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| CN107683138A (zh) | 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 | |
| JP2019501879A5 (https=) |